GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Vamifeport

Company
CSL Behring
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Vamifeport and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07332091

    Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

    Not yet reported CSL Behring 84 participants Est. completion 2028-05-15 100 sites Stand-alone
    Other conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
    View official trial listing →
  • Completed NCT NCT04817670

    Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

    Not yet reported Vifor (International) Inc. 25 participants Est. completion 2024-03-07 22 sites
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Withdrawn NCT NCT04938635

    Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

    Not yet reported Vifor (International) Inc. Est. completion 2023-07 7 sites
    Other conditions: Beta-Thalassemia
    View official trial listing →
  • Completed NCT NCT05077436

    Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

    Not yet reported Vifor (International) Inc. 28 participants Est. completion 2022-01-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06726863

    Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults

    Not yet reported CSL Behring 22 participants Est. completion 2025-02-01 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT06996184

    Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults

    Not yet reported CSL Behring 28 participants Est. completion 2025-07-04 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.